Education
About Us
Working with TipRanks
Follow Us
Exact Sciences Corp. (EXAS)
NASDAQ:EXAS
EXAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$39.97 - $72.83
Previous CloseN/A
Volume846.89K
Average Volume (3M)2.94M
Market Cap
$10.05B
Enterprise Value$10.94B
Total Cash (Recent Filing)$786.17M
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 05, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding188,637,680
10 Day Avg. Volume2,371,909
30 Day Avg. Volume2,941,442
Financial Highlights & Ratios
PEG Ratio-8.12
Price to Book (P/B)2.87
Price to Sales (P/S)0.00
P/FCF Ratio-19.93
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit5.67
Enterprise Value/Ebitda-7.04
Forecast
1Y Price Target
$70.25Price Target Upside31.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
Exact Sciences News
PremiumCompany Announcements
Exact Sciences Shareholders Approve 2025 Incentive Plan
PremiumCompany Announcements
Exact Sciences Corp Reports Strong Start to 2025
Bulls Say, Bears Say
Bulls Say
Growth And GuidanceEXAS management feels very strong about near-term growth and there could be upside to 2025 guidance.
NCCN Guideline InclusionNCCN added LBx to its CRC screening guidelines, giving it the same level of evidence as colonoscopies and Cologuard.
Product PerformanceEXAS delivered a strong beat and even higher guide raise on Cologuard, giving confidence in product performance and market positioning.
Bears Say
Market RelevanceNCCN guidelines are less relevant to PCPs, which is where the bulk of screening takes place, and guidelines from other institutions will be much more meaningful in terms of driving adoption of blood-based CRC screening tools.
NCCN Guideline LimitationsAnalysts believe NCCN guidelines alone are not enough to drive coverage expansion beyond Medicare.
Ownership Overview
1.04% Insiders
44.38% Mutual Funds
29.17% Other Institutional Investors
11.23% Public Companies and Individual Investors
EXAS FAQ
What was Exact Sciences Corp.’s price range in the past 12 months?
Exact Sciences Corp. lowest stock price was $39.97 and its highest was $72.83 in the past 12 months.
What is Exact Sciences Corp.’s market cap?
Exact Sciences Corp.’s market cap is $10.05B.
When is Exact Sciences Corp.’s upcoming earnings report date?
Exact Sciences Corp.’s upcoming earnings report date is Aug 05, 2025 which is in 48 days.
How were Exact Sciences Corp.’s earnings last quarter?
Exact Sciences Corp. released its earnings results on May 01, 2025. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.375 by -$0.165.
Is Exact Sciences Corp. overvalued?
According to Wall Street analysts Exact Sciences Corp.’s price is currently Undervalued.
Does Exact Sciences Corp. pay dividends?
Exact Sciences Corp. does not currently pay dividends.
What is Exact Sciences Corp.’s EPS estimate?
Exact Sciences Corp.’s EPS estimate is -0.12.
How many shares outstanding does Exact Sciences Corp. have?
Exact Sciences Corp. has 188,637,680 shares outstanding.
What happened to Exact Sciences Corp.’s price movement after its last earnings report?
Exact Sciences Corp. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.375. Following the earnings report the stock price went up 9.309%.
Which hedge fund is a major shareholder of Exact Sciences Corp.?
Currently, no hedge funds are holding shares in EXAS
Exact Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.25 (31.80% Upside)
$70.25 (31.80% Upside)
Blogger Sentiment
Bullish
EXAS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 948.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.26%
12-Months-Change
Fundamentals
Return on Equity
-36.89%
Trailing 12-Months
Asset Growth
-10.43%
Trailing 12-Months
Company Description
Exact Sciences Corp.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
EXAS Company Deck
EXAS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, improved profitability, and successful product launches, indicating a strong start to 2025. However, challenges with commercial payer coverage for new products and the impact of a severe flu season were noted.Read More>EXAS Revenue Breakdown
74.59% Screening
25.17% Precision Oncology
0.24% COVID-19 Testing
EXAS Stock 12 Month Forecast
Average Price Target
$70.25
▲(31.80%Upside)